GigaGen

34 articles with GigaGen

• GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens

  9/15/2022

  GigaGen Inc. announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.

• GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies

  7/28/2022

  GigaGen Inc. announced today the publication of a research article titled, “GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,” in the international, peer-reviewed journal Pathogens.

• GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development

  5/19/2022

  GigaGen Inc. announced the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.

• GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates

  9/30/2021

  GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.

• 

  Clinical Catch-Up: August 9-13

  8/16/2021

  There was plenty of clinical trial updates last week. Here’s a look.

• GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature BiotechnologyArticle describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy

  4/15/2021

  GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Generation of recombinant hyperimmune globulins from diverse B cell repertoires,” in the peer-reviewed journal Nature Biotechnology.

• GigaGen Announces Publication in the Peer-Reviewed Journal mAbsArticle Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge Platform

  10/20/2020

  GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data detai

• 

  GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy

  8/10/2020

  Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising.

• GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050

  8/10/2020

  GIGA-2050 is like a "recombinant convalescent serum," enabling production of millions of doses of drug from a few donors

• 

  Biopharma Update on the Novel Coronavirus: August 10

  8/10/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.

• GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium

  7/29/2020

  GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020. Presentation Details: Date:     Tuesday, August 4, 2020 Time:   11:30 am PT / 2:30 pm ET Registration:  

• 

  GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy

  3/30/2020

  First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.

• GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19

  3/30/2020

  GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19.

• 

  Biopharma Update on the Novel Coronavirus: March 30

  3/30/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
• 

  GigaGen’s Recombinant IVIG Technology Could Be Potential Solution to Global Shortage

  12/10/2019

  A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients.

• GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies

  7/18/2019

  GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company's Surge™ technology

• 

  6 Award-Winning Life Science Companies in the Bay Area

  4/19/2019

  Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.

• GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies

  3/25/2019

  Findings show that performing multiple immunization protocols in parallel can yield greater antibody diversity

• GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting

  2/24/2019

  GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting.

• GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires

  2/20/2019

  Findings show utilizing cell lysate and Surge technology for antibody selection yielded antibodies with higher potential as therapeutic agonists